Study wrapper · #318
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Editor's note
Bremelanotide features here only as a worked example in a chemistry-and-history review of FDA-approved drugs built from D-amino acids — the mirror-image forms of the body's standard L-amino acids. It is not an efficacy study and says nothing new about whether the peptide works. Its value for readers is mechanistic context: D-amino-acid substitutions resist the proteases that rapidly degrade ordinary peptides, which is part of why engineered melanocortin peptides like bremelanotide are stable enough to be viable drugs. The review situates bremelanotide alongside desmopressin, leuprolide, and etelcalcetide as instances of this design strategy, enabled by solid-phase peptide synthesis and mirror-image phage display. Weight it as background on peptide drug design, not as clinical evidence. Nothing here speaks to bremelanotide's effect size, safety in any population, or its narrow FDA-approved indication.
Plain-language abstract
Amino acids, the building blocks of peptides and proteins, usually come in a "left-handed" (L) form in the body. Their mirror-image "right-handed" (D) versions are rare in nature but useful in drug design: enzymes that normally chop up peptides struggle to recognize the mirror-image building blocks, so drugs made with them last longer in the body, hold their shape better, and are less likely to provoke an immune reaction. This review traces how, since the mid-20th century, more than 20 FDA-approved drugs have included at least one D-amino acid. Examples range from natural products like gramicidin D to synthetic peptides such as desmopressin, leuprolide, bremelanotide, and etelcalcetide — the last being the first approved drug made entirely from D-amino acids. The article explains the mechanisms and medical uses of these drugs and the lab techniques that made them possible, including solid-phase peptide synthesis and mirror-image phage display. It is a historical and technical overview, not a study of how well any single drug performs.